

4 June 2021

**Diaceutics PLC
("Diaceutics" or the "Company")**

Diaceutics to release breakthrough data on COVID-19 impact on cancer at 2021 American Society of Clinical Oncology (ASCO) Meeting

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, today announces the acceptance of an abstract for a poster discussion presentation, discussing the impact of COVID-19 on cancer diagnosis, at the prestigious 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.

The ASCO Annual Meeting represents the world's largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology. This year, ASCO received and reviewed more than 5,400 abstracts for the 2021 ASCO Annual Meeting, ultimately selecting the final entries to be presented on a set of criteria including the strength and relevance of the research and whether it addresses an important and novel question.

Diaceutics will present data and findings from a study into the impact of the COVID-19 pandemic on the volume of surgical pathology (SP) and immunohistochemistry (IHC) used. These are important methods associated with primary diagnosis, tumour staging and treatment management decisions, across 11 solid tumour cancers.

The presentation of Diaceutics' analysis of the impact of COVID-19 on cancer diagnosis and treatment at this prestigious event supports the Company's engagement with its pharmaceutical clients in this important emerging impact on patients' access to treatment.

"We look forward to sharing our data which highlight a period of decline in patient testing related to diagnosis and management, for all 11 cancers examined, that is linked to COVID-19 mitigation strategies in the US population," said Keith Kerr, Professor of Pulmonary Pathology, Aberdeen Royal Infirmary and Advisor at Diaceutics. "The data that will be presented at this year's ASCO continue to highlight the potential of Diaceutics to enable better testing and ultimately better treatment for patients with cancer."

Enabled by DXRX - The Diagnostic Network®, Diaceutics provides seamless diagnostic testing for precision medicines through deep analysis and disease level-understanding of the testing journey. Through the extraction of insights from the world's richest repository of diagnostic testing data available via its DXRX platform, the company leverages unique proprietary Disease Diagnostic Pathways (DDPs®) to identify the best possible testing journey for patients within a specific disease or disease area.

Details of the presentations are as follows:

Significant decline in cancer diagnostic testing in US CMS population during the COVID-19 pandemic - Abstract #336339

- Session Title: Poster Session: Health Services Research and Quality Improvement
- Authors: Dave Smart, Peter Riccelli, Keith Kerr, Jordan Clark, Susanne Munksted, Mark Lawler
- Access to the study can be gained via the following company webpage: <https://lp.diaceutics.com/asco-2021-poster/>

Information about the 2021 ASCO Annual Meeting may be accessed via the following website: <https://conferences.asco.org/am/registration>.

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Alma PR

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)
Ben Maddison
Stewart Wallace
Nick Adams

+44 (0)20 7710 7600

Alma PR
Caroline Forde
Robyn Fisher
Kieran Breheny

Tel: +44 (0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASSIESDEFSEFM